COPELLOR 80 mg/mL Injection COPELLOR contains Ixekizumab, a humanized IgG4 monoclonal antibody that selectively binds to interleukin-17A (IL-17A) cytokine with high affinity and neutralizes its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that plays a central role in driving inflammatory and immune responses. By inhibiting IL-17A, ixekizumab suppresses the release of proinflammatory cytokines and chemokines that contribute to epidermal hyperplasia and chronic systemic inflammation. It is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis.